Published in Neurology on November 10, 2010
Creatine Safety and Tolerability in Premanifest HD: PRECREST (PRECREST) | NCT00592995
Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep (2011) 1.55
Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry (2012) 1.06
Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology (2012) 1.00
Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials (2012) 1.00
Unbiased and mobile gait analysis detects motor impairment in Parkinson's disease. PLoS One (2013) 0.99
Tracking motor impairments in the progression of Huntington's disease. Mov Disord (2013) 0.98
Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis (2013) 0.95
Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study. J Psychiatry Neurosci (2014) 0.92
Impaired motor speech performance in Huntington's disease. J Neural Transm (Vienna) (2013) 0.87
Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease. Brain Behav (2013) 0.85
Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. PLoS One (2015) 0.85
Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease. Front Syst Neurosci (2014) 0.81
Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingtons Dis (2013) 0.81
Neuropsychiatry and White Matter Microstructure in Huntington's Disease. J Huntingtons Dis (2015) 0.78
Time Processing and Motor Control in Movement Disorders. Front Hum Neurosci (2016) 0.78
Variability in interval production is due to timing-dependent deficits in Huntington's disease. Mov Disord (2014) 0.78
Tapping in Huntington disease: a path forward to preventive therapies? Neurology (2010) 0.77
Music perception and movement deterioration in Huntington's disease. PLoS Curr (2011) 0.77
Degradation of cognitive timing mechanisms in behavioural variant frontotemporal dementia. Neuropsychologia (2014) 0.77
Cholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input. J Comp Neurol (2016) 0.77
Novel Nut and Bolt Task Quantifies Motor Deficits in Premanifest and Manifest Huntington's Disease. PLoS Curr (2015) 0.75
Striatal morphology correlates with frontostriatal electrophysiological motor processing in Huntington's disease: an IMAGE-HD study. Brain Behav (2016) 0.75
Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues. PLoS One (2015) 0.75
Quantitative motor assessment of dyskinesias in Parkinson's disease. J Neural Transm (Vienna) (2015) 0.75
The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia (1971) 86.03
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord (1996) 8.02
What makes us tick? Functional and neural mechanisms of interval timing. Nat Rev Neurosci (2005) 7.51
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol (1997) 4.01
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature (2000) 2.81
Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 2.49
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain (2008) 2.40
CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet (2010) 2.31
Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord (2006) 2.23
fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol (2004) 2.10
Issues with threshold masking in voxel-based morphometry of atrophied brains. Neuroimage (2008) 2.00
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord (2009) 1.73
Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology (1994) 1.61
Regional cerebral blood flow during voluntary arm and hand movements in human subjects. J Neurophysiol (1991) 1.50
Lateralization of motor circuits and handedness during finger movements. Eur J Neurol (2001) 1.48
Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res (2005) 1.43
Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol (1999) 1.41
Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc (2007) 1.38
Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex (2004) 1.32
Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord (2008) 1.30
Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol (2000) 1.21
White matter volume predicts reaction time instability. Neuropsychologia (2007) 1.18
Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord (2005) 1.13
Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain (2009) 1.11
Assessment of simple movements reflects impairment in Huntington's disease. Mov Disord (2006) 1.11
Functional imaging in Huntington's disease. Exp Neurol (2009) 1.08
Central motor processing in Huntington's disease. A PET study. Brain (1997) 1.03
Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology (2001) 1.03
Impairment of rapid movement in Huntington's disease. Brain (1987) 0.99
Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J Neurol (2008) 0.99
Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum Brain Mapp (2009) 0.94
Time processing in Huntington's disease: a group-control study. PLoS One (2007) 0.93
Assessment of simple movements and progression of Huntington's disease. J Neurol Neurosurg Psychiatry (2007) 0.91
Abnormalities of motor timing in Huntington's disease. Parkinsonism Relat Disord (1996) 0.85
Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord (1998) 0.84
Haplotype variation and linkage disequilibrium in 313 human genes. Science (2001) 8.52
Public health. Grand Challenges in Global Health. Science (2003) 7.91
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain (2006) 5.55
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology (2002) 5.40
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
Induction of neurogenesis in the neocortex of adult mice. Nature (2000) 5.04
Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet (2001) 4.28
Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology (2005) 3.90
The CIC library: a large insert YAC library for genome mapping in Arabidopsis thaliana. Plant J (1995) 3.79
Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging (2001) 3.68
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol (2001) 3.43
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Correlation between rates of brain atrophy and cognitive decline in AD. Neurology (1999) 3.07
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.75
A one-hit model of cell death in inherited neuronal degenerations. Nature (2000) 2.65
TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol (1999) 2.61
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths. Neuroimage (2007) 2.23
Age-related changes in prefrontal white matter measured by diffusion tensor imaging. Ann N Y Acad Sci (2005) 2.18
Factors influencing wound dehiscence. Am J Surg (1992) 2.17
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem (2000) 2.14
Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun (1991) 2.13
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology (2012) 2.12
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 2.10
Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology (2001) 2.09
Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun (2011) 2.04
Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology (2009) 2.04
White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging (2010) 2.01
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology (2005) 1.95
Saccades in presymptomatic and early stages of Huntington disease. Neurology (2006) 1.92
Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain (2009) 1.91
Age-associated alterations in cortical gray and white matter signal intensity and gray to white matter contrast. Neuroimage (2009) 1.85
Oligophrenin 1 mutations frequently cause X-linked mental retardation with cerebellar hypoplasia. Neurology (2005) 1.85
An improved approach to prepare human brains for research. J Neuropathol Exp Neurol (1995) 1.84
Marital quality, marital disruption, and immune function. Psychosom Med (1987) 1.81
Complete sequence of one of the mRNAs coding for the small subunit of ribulose bisphosphate carboxylase of Nicotiana sylvestris. Biochimie (1985) 1.77
Expression of the gene coding for the small subunit of ribulosebisphosphate carboxylase during differentiation of tobacco plant protoplasts. Eur J Biochem (1982) 1.76
NMDA receptor function in mouse models of Huntington disease. J Neurosci Res (2001) 1.76
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology (2006) 1.73
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain (2002) 1.71
Automated hippocampal segmentation by regional fluid registration of serial MRI: validation and application in Alzheimer's disease. Neuroimage (2001) 1.71
Weight loss in Huntington disease increases with higher CAG repeat number. Neurology (2008) 1.66
Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer (2006) 1.66
Anatomical distribution of colonic carcinomas. Interracial differences in a community hospital population. Cancer (1986) 1.64
Transient anisocoria secondary to nebulized ipratropium bromide. Clin Pediatr (Phila) (1998) 1.60
Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study. Exp Neurol (2012) 1.56
Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem (1999) 1.52
Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology (2006) 1.52
Strangulated Diaphragmatic Hernia in an Infant. Cal West Med (1932) 1.50
Folic acid and prevention of neural tube defects in 2000 improved awareness--low peri-conceptional uptake. Ir Med J (2001) 1.49
Missense CACNA1A mutation causing episodic ataxia type 2. Arch Neurol (2001) 1.44
Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ (2004) 1.44
Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology (2011) 1.43
Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem (1991) 1.42
Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol (1999) 1.41
De novo nonreciprocal translocation 1;8 confirmed by fluorescent in situ hybridization. Am J Med Genet (1995) 1.41
A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. Neuroimage (2008) 1.40
Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology (2000) 1.40
Demographic profile of the elderly population in Dublin accident and emergency hospital catchment areas. Ir Med J (2004) 1.39
Multiparameter MR imaging in the 6-OPRI variant of inherited prion disease. AJNR Am J Neuroradiol (2013) 1.39
Role of robot-assisted laparoscopy in adjuvant surgery for locally advanced cervical cancer. Eur J Surg Oncol (2010) 1.39
Extra corporeal shock wave lithotripsy of calculi located in lower calyx of left kidney in a spinal cord injury patient who has implantation of baclofen pump in the ipsilateral loin. Spinal Cord (2002) 1.39
Time to reinvent the wheel. Br J Obstet Gynaecol (1993) 1.38
Obstetric events leading to anal sphincter damage. Obstet Gynecol (1998) 1.35
Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry (2004) 1.35
One-year outcome after decompressive surgery for massive nondominant hemispheric infarction. Neurosurgery (1997) 1.33
B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci U S A (2000) 1.31
Assessing frontal lobe behavioral syndromes with the frontal lobe personality scale. Assessment (1999) 1.31
Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med (1995) 1.31
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol (1997) 1.29
Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem (2001) 1.28
Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience (1999) 1.28
Isolation and characterization of a plant cDNA showing homology to animal glutathione peroxidases. Plant Mol Biol (1992) 1.27
Universal vs. risk factor-based screening for gestational diabetes mellitus: detection rates, gestation at diagnosis and outcome. Diabet Med (2000) 1.27
Permanent removal of pigmentation from giant hairy naevi by dermabrasion in early life. Br J Plast Surg (1977) 1.26
Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology (2009) 1.22
Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc Natl Acad Sci U S A (2006) 1.21
Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol (2000) 1.21
Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res (1996) 1.21
Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia. Neurology (2006) 1.20
Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res (2004) 1.20
1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology (1998) 1.20
Verbal memory performance of patients with human immunodeficiency virus infection: evidence of subcortical dysfunction. The HNRC Group. J Clin Exp Neuropsychol (1994) 1.20
Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci (1990) 1.18
Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol (1998) 1.18
Behavioural risk factors among young adults in small areas with high mortality versus those in low-mortality areas. Int J Epidemiol (1991) 1.18
The differential diagnosis of chorea. Pract Neurol (2007) 1.18
Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet (2000) 1.17
An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol (1998) 1.17